| Name | Title | Contact Details |
|---|
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.
Cardinal Health, Inc. is an American multinational health care services company, and the 14th highest revenue generating company in the United States.
BN ImmunoTherapeutics is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Shimadzu Corporation is a Japanese public KK company, manufacturing precision instruments, measuring instruments and medical equipment, based in Kyoto, Japan.
NVE Pharmaceuticals is a Andover, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.